TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects must have cytologically or histologically confirmed ovarian, primary peritoneal or fallopian tube cancer.. In addition, subjects must have a tumor that is at least 1 cm in a single dimension and is radiographically apparent on CT, PET-CT or MRI (i.e., RECIST version 1.1 measurable disease).~2. Subjects must have platinum resistant disease (i.e., which is defined as disease progression in less than 6 months after receiving a minimum of 4 cycles of a platinum containing regimen).~3. Subjects with the following histologic epithelial cell types are eligible: Serous adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, transitional cell carcinoma, malignant Brenner's Tumor, or adenocarcinoma N.O.S.~4. Age \>21 years~5. ECOG performance status \<3~Exclusion Criteria:~1. Subjects receiving any other investigational medicinal product or anti-cancer therapy.~2. Prior therapy with weekly paclitaxel for recurrent disease (administration of weekly paclitaxel as part of an upfront treatment strategy is acceptable as long as the patient had not progressed while receiving weekly paclitaxel or recurred within 4 months of receiving weekly paclitaxel)~3. Non-epithelial ovarian carcinoma, including malignant mixed Mullerian tumors.~4. For the Phase 1b portion of the study, more than 3 prior chemotherapy regimens and for the Phase 2 portion of the study more than 2 prior chemotherapy regimens. Maintenance therapy following induction chemotherapy does not count as a separate regimen. In addition, hormonal therapy (e.g., tamoxifen or an aromatase inhibitor) does not count as a separate regimen.~5. Prior radiotherapy to the pelvis or abdomen~6. Subjects receiving heparin, warfarin, or other similar anticoagulants. Note: Subjects may be receiving lowdose aspirin and/or non-steroidal anti-inflammatory agents.

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Demcizumab (Type: EXPERIMENTAL): Demcizumab will be administered prior to paclitaxel by intravenous (IV) infusion.
- Taxol (Type: EXPERIMENTAL): demcizumab combined with weekly paclitaxel

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Study of BN83495 in Post-menopausal Women With Endometrial Cancer Post-chemotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of written informed consent prior to any study related procedures.~* postmenopausal or ovariectomised female patient over 18 years of age.~* histologically confirmed diagnosis of ER positive endometrial carcinoma in the primary tumour or metastatic disease~* patient has received one line of chemotherapy prior to enrolment in the adjuvant or in the metastatic setting (including chemoradiotherapy) and progressed after this line of chemotherapy~* patient has at least one measurable disease site (RECIST criteria version 1.1)~Exclusion Criteria:~* patient has received hormone therapy for endometrial cancer in the adjuvant or metastatic setting~* patient has received more than one line of chemotherapy in the adjuvant or metastatic setting~* patient was treated with any other investigational agent within the 3 weeks before study entry.~* patient has ongoing cardiac dysrhythmias grade ≥2, atrial fibrillation of any grade (NCI CTCAE) or QTcF interval \>460 msec.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BN83495 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Nicotine Patch for Nicotine Dependence in Individuals With Schizophrenia or Schizoaffective Disorder - 1

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Subjects: 100 stable outpatients with schizophrenia and schizoaffective disorder and nicotine dependence. All subjects will meet the following inclusion criteria:~* Patients who are able to provide informed consent~* Patients will meet DSM-IV diagnostic criteria for Nicotine Dependence and Schizophrenia or Schizoaffective disorder~* Patients will be stable on their current antipsychotic regimen and will be interested in treatment for both their psychiatric and nicotine dependence~Exclusion Criteria:~* Potential subjects meeting the following criteria will be excluded:~* Patients with history of clinically significant angina or unstable angina pectoris~* Patients with severe CAD or recent myocardial infarction (within last 6 months)~* Patients with evidence or history of other severe medical illness (hematologic, renal or neoplastic)~* Patients who represent a serious suicide risk, including recent suicidal behavior or attempt within the last thirty days~* Patients with history of severe skin allergies or chronic dermatoses~* Concomitant use of clonidine or bupropion~* Pregnant females

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Early Closure Versus Conventional Closure in Postoperative Patients With Low Anteriresection for Rectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~Patients older than 18 years Diagnosis of Rectal cancer treated at the National Institute of Cancerology and any of the institutions attached to the study~Exclusion criteria:~Complications derived from the anterior resection of the rectum:~* Unresolved intestinal obstruction~* Sepsis~* Organ or space type operative site infection~* Hemodynamic inestability~* Need for reinterventions due to complications~* Coagulopathy~* Active bleeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Early closure of ileostomy (Type: EXPERIMENTAL): Early clousure of ileostomy before 30 days
- Conventional closure of ileostomy (Type: ACTIVE_COMPARATOR): Conventional closure of ileostomy after 30 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: King Vision Video Laryngoscope Versus Glidescope Video Laryngoscope

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients scheduled for elective, ambulatory surgery requiring general anesthesia and endotracheal intubation~Exclusion Criteria:~* Patients who require rapid sequence induction and intubation or fiberoptic intubation.~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- King Vision Video Laryngoscope (Type: ACTIVE_COMPARATOR): The patient would be randomized to intubation via use of the King Vision VL
- Glidescope Video Laryngoscope (Type: ACTIVE_COMPARATOR): The patient would be randomized to intubation via use of the Glidescope VL

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Insulin Sensitivity and Substrate Metabolism in Patients With Cushing's Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Written consent~* Age between 18 and 70~* Diagnosed with Cushing's syndrome~Exclusion Criteria:~* Suspected malignancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: None): Patients recently diagnosed with Cushing's syndrome

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Midfoot Fusion Bolt (MFB) in the Early Stage of Diabetic-neuropathic Charcot Feet

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years~* Patients with Diabetes Mellitus Type I or II~* CN stages 0, 1 or 2 of the midfoot (Sella and Barrette classification)~* Willingness and ability to participate in the study follow-up according to the protocol~* Ability to understand and read local language at elementary level~* Signed informed consent~Exclusion Criteria:~* Legal incompetence~* Previous Charcot foot on the affected side~* Active osteomyelitis in the affected foot~* Above knee amputation on the contralateral side~* Patient health status not adequate for surgery~* Active malignacy~* Severe peripheral arterial disease (ankle-brachial index \<0.7 or absent digital waveforms on Doppler)~* Ulcer grade 2 or more on the Wagner classification system~* Alcohol or drug abuse~* Life-threatening co-morbidities

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Midfoot Fusion Bolt (Type: EXPERIMENTAL): None
- Cast treatment (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Outpatient Recovery From Acute Kidney Injury Requiring Dialysis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* AKI-D (acute kidney injury requiring dialysis), attributed at least in part to acute tubular necrosis by clinical nephrology team~* Age ≥ 18 years~* Pre-hospitalization eGFR ≥ 15 mL/min/1.73m2~* Being discharged to a participating outpatient dialysis unit (within 30 miles of UCSF)~Exclusion Criteria:~* Known loop diuretic allergy/intolerance~* Dialysis duration \> 3 months~* Pregnant~* Prisoner~* Unable to consent~* Clinical team declines to allow approach for study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ORKID Bundled Intervention (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Investigation of Corticosteroid Versus Placebo Injection in Patients With Syndesmotic Ligament Injury or High Ankle Sprain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 16 years or older~* Musculoskeletal ultrasound performed which demonstrates injury pattern consistent with high ankle sprain.~* Must sign the informed consent form and agree to meet the needs of the study~* Clinically and ultra sound confirmed and isolated syndesmotic ligament injury or high ankle sprain without associated fracture~* Injury occurred within the previous 7 days~Exclusion Criteria:~* Surgical intervention required to stabilize the ankle~* Unable to read and understand the consent form~* Unable to meet the needs of the follow-up examinations~* Allergic to the betamethasone~* Current fungal infection~* Pregnancy or currently breast feeding

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- bupivacaine hydrochloride and betamethasone sodium phosphate (Type: EXPERIMENTAL): When the patient has been randomized to either group, a licensed provider under the direction of the PI, will utilize the ultrasound to identify the inferior tibiofibular ligament (syndesmotic ligament). This provider that performs the injection will not be involved in any follow-up visits or return to play review. When appropriate positioning is confirmed the area will be injected with a mixture of 5 ml of 0.25 % bupivacaine hydrochloride and 2 ml of 3 mg/ml betamethasone sodium phosphate (Celestone® Soluspan®) (BTM)
- bupivacaine hydrochloride (Type: ACTIVE_COMPARATOR): When the patient has been randomized to either group, a licensed provider under the direction of the PI, will utilize the ultrasound to identify the inferior tibiofibular ligament (syndesmotic ligament). This provider that performs the injection will not be involved in any follow-up visits or return to play review. When appropriate positioning is confirmed, the area will be injected with 5ml of bupivacaine hydrochloride.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Methylation Pattern of DNA in Buccal Swabs From Different Time Points

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Caucasian~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Volunteers (Type: None): 30 volunteers, half men and half women Buccal swab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Study on Severe Infections on Acute Myeloid Leukemia (AML) Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All patients enrolled in the GIMEMA AML1310 study;~* Signed written informed consent according to ICH/EU/GCP and national local laws.~Exclusion Criteria:~* Patients not eligible for the GIMEMA AML1310 study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- All patients enrolled in the GIMEMA AML1310 study. (Type: None): * All patients enrolled in the GIMEMA AML1310 study;~* Signed written informed consent according to ICH/EU/GCP and national local laws.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Computed Tomography (CT) in Head and Neck Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with squamous cell carcinoma of the head and neck~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: ITI-007 (Lumateperone Tosylate) for Schizophrenia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) diagnosis of schizophrenia or schizoaffective disorder~* Has capacity to provide informed consent~* Medically stable for study participation~* Judged clinically not to be at significant suicide or violence risk~* Inadequate response or tolerability to previously antipsychotic therapy, as defined by at least one of the following: prior clozapine failure, a PANSS\>80 despite at least six weeks of a current antipsychotic therapy, a Clinical Global Impressions scale-Improvement (CGI-I) of 4 after at least two six week trials of antipsychotics (retrospective assessment) or failure to tolerate an adequate dose of at least antipsychotics (as defined by the Physicians Desk Reference)~Exclusion Criteria:~* Substance abuse within last 90 days~* ECG abnormality that is clinically significant~* Pregnancy, lactation, or lack of use of effective birth control~* Presence or positive history of significant unstable medical or neurological illness (including any history of seizure disorder, hepatitis, renal insufficiency or mental retardation), history of HIV~* Clinically significant abnormal laboratory tests, positive for hepatitis B or C or liver function tests (LFTs) \> 2x Upper Limit of Normal, use of strong CYP3A4 inhibitors or inducers~* History or presence of concomitant major psychiatric illness.~* Use of other antipsychotic medications at baseline.~* Use of another investigational medication in the previous 4 weeks

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- ITI-007 (Type: EXPERIMENTAL): Open-Label ITI-007 40-60 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Video Assisted Thoracoscopic Surgery (VATS) Versus Open Surgery for Patients Undergoing Lobectomy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject must be 18 years of age or older.~* Subject must have been clinically diagnosed with stage I to stage IIA non small cell lung cancer measuring and judged to be resectable.~* Subject must be able to tolerate general anesthesia, and have cardiopulmonary reserve to tolerate a lobectomy~Exclusion Criteria:~* Subject is pregnant (documented by pregnancy test) or breastfeeding.~* Subject has other severe illnesses that would preclude surgery such as~  * Unstable angina~ * Myocardial Infarction within 3 months~ * Coronary Artery Bypass Graft Surgery~* Subject has other active cancers~* Subject is unable to comply with any of the following:~  * Study requirements~ * Give valid informed consent~ * Follow-up schedule

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A (Type: None): VATS
- Group B (Type: None): Open Surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Acute Defibrillation Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must be undergoing surgical procedure for approved indications for~* cardiothoracic surgery where a midline sternotomy is planned, or~* implant of a transvenous (TV) ICD or subcutaneous ICD (S-ICD®), or~* VT ablation procedure, or~* VT inducibility testing during Electrophysiology (EP) study~* Subject must be willing to provide Informed Consent~* Subject must be ≥ 18 years old~Exclusion Criteria:~* Subject is considered to be at high risk for infection~* Subject has Left Ventricular Ejection Fraction (LVEF) ≤ 20%~* Subject at high risk of stroke~* Subject with an implanted active cardiac or non-cardiac device during study procedure (e.g., ICD, S-ICD®, Pacemaker, Neuro stimulator)~* Subject is pacemaker dependent~* Subject had previous pericarditis or prior sternotomy~* Subject has hiatus hernia or moderate or worse pectus excavatum~* Subject has hypertrophic cardiomyopathy~* Subject has severe aortic stenosis~* Subject has severe proximal three vessel coronary disease (over 70% in each vessel)~* Subject has \>50% left main stem (LMS) disease~* Subject has known skin irritations to the Physio Control Fast Patch ECG Electrode~* Subject is enrolled in a concurrent study that may confound the results of this study, without documented pre-approval from a Medtronic study manager~* Subject has medical conditions that would limit study participation~* Subject is pregnant~* Subject meets exclusion criteria required by local law (e.g. age, breast feeding, etc.)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VT/VF induction and defibrillation (Type: EXPERIMENTAL): Ventricular Tachycardia and Ventricular Fibrillation (VT/VF) induction and defibrillation will be carried out as the invention in all subjects undergoing study procedures.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues